Shopping Cart

There are no products in your cart.

Ingrid Burvenich

POSTDOCTORAL RESEARCH FELLOW

More about Ingrid Burvenich

The ongoing objective of my work is to image and improve drug delivery and efficacy in cancer patients.

After finishing my PhD in Ghent, I joined the Ludwig Insitute for Cancer Research as a postdoctoral research fellow to further my expertise in antibody characterization, antibody engineering and pre-clinical in vitro and in vivo evaluation of antibodies. My postdoctoral studies at Ludwig focused on the Fc domain engineering of an anti-Lewis Y antibody (hu3S193) to optimize the pharmacokinetic properties for payload strategies such as radioimmunotherapy and enhance activation of immune effector functions. In parallel, I have been involved in the preclinical development of a death receptor 5 (DR5) agonist antibody for use as a clinical bioimaging reagent; the preclinical development of an anti-EphA2 antibody for use as a clinical bioimaging reagent and the humanisation and preclinical evaluation of an anti-PDGF-CC antagonist antibody.

My current project at the Olivia Newton-John Cancer Research Institute focuses on imaging lipid changes in prostate cancer through combined imaging modalities.